Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Lerch

Showing results (561-570 of 640) with videos related to

Pageof 64
Sort By:
Zeitschrift Fur Gastroenterologie|September 14, 2017
[Cost assessment for endoscopic procedures in the German diagnosis-related-group (DRG) system - 5 year cost data analysis of the German Society of Gastroenterology project]Markus Rathmayer, Wolfgang Heinlein, Claudia Reiß, et al.
Deutsches Arzteblatt International|September 24, 2016
Fecal Microbiota Transplant in Patients With Recurrent Clostridium Difficile InfectionStefan Hagel, Anne Fischer, Philipp Ehlermann, et al.
Brain, Behavior, and Immunity|April 8, 2026
Bilophila wadsworthia is linked to basal ganglia atrophy in the general populationDaniel Fässler, Katharina Wittfeld, Stefan Frenzel, et al.
BMJ Open|September 5, 2019
Observational longitudinal multicentre investigation of acute pancreatitis (GOULASH PLUS): follow-up of the GOULASH study, protocolAlexandra Mikó, Bálint Erőss, Patrícia Sarlós, et al.
International Journal of Cancer|October 8, 2008
Investigation of the colorectal cancer susceptibility region on chromosome 8q24.21 in a large German case-control sampleClemens Schafmayer, Stephan Buch, Henry Völzke, et al.
The American Journal of Gastroenterology|October 25, 2018
Identification of Cystic Lesions by Secondary Screening of Familial Pancreatic Cancer (FPC) Kindreds Is Not Associated with the Stratified Risk of CancerA R G Sheel, S Harrison, I Sarantitis, et al.
International Journal of Cancer|August 25, 2021
Early weight loss is an independent risk factor for shorter survival and increased side effects in patients with metastatic colorectal cancer undergoing first-line treatment within the randomized Phase III trial FIRE-3 (AIO KRK-0306)Lian Liu, Nicole Tonya Erickson, Ingrid Ricard, et al.
Pancreatology : Official Journal of the International Association of Pancreatology (IAP) ... [Et Al.]|May 8, 2020
International Consensus Guidelines for Risk Factors in Chronic Pancreatitis. Recommendations from the working group for the international consensus guidelines for chronic pancreatitis in collaboration with the International Association of Pancreatology, the American Pancreatic Association, the Japan Pancreas Society, and European Pancreatic ClubPéter Hegyi, Andrea Párniczky, Markus M Lerch, et al.
Gastroenterology|June 7, 2021
Tumor-Specific Delivery of 5-Fluorouracil-Incorporated Epidermal Growth Factor Receptor-Targeted Aptamers as an Efficient Treatment in Pancreatic Ductal Adenocarcinoma ModelsUjjwal M Mahajan, Qi Li, Ahmed Alnatsha, et al.
The Lancet. Oncology|August 31, 2016
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trialSebastian Stintzing, Dominik P Modest, Lisa Rossius, et al.
Pageof 64

Showing results (561-570 of 640) with videos related to

Sort By:
Pageof 64
Zeitschrift Fur Gastroenterologie|September 14, 2017
[Cost assessment for endoscopic procedures in the German diagnosis-related-group (DRG) system - 5 year cost data analysis of the German Society of Gastroenterology project]Markus Rathmayer, Wolfgang Heinlein, Claudia Reiß, et al.
Deutsches Arzteblatt International|September 24, 2016
Fecal Microbiota Transplant in Patients With Recurrent Clostridium Difficile InfectionStefan Hagel, Anne Fischer, Philipp Ehlermann, et al.
Brain, Behavior, and Immunity|April 8, 2026
Bilophila wadsworthia is linked to basal ganglia atrophy in the general populationDaniel Fässler, Katharina Wittfeld, Stefan Frenzel, et al.
BMJ Open|September 5, 2019
Observational longitudinal multicentre investigation of acute pancreatitis (GOULASH PLUS): follow-up of the GOULASH study, protocolAlexandra Mikó, Bálint Erőss, Patrícia Sarlós, et al.
International Journal of Cancer|October 8, 2008
Investigation of the colorectal cancer susceptibility region on chromosome 8q24.21 in a large German case-control sampleClemens Schafmayer, Stephan Buch, Henry Völzke, et al.
The American Journal of Gastroenterology|October 25, 2018
Identification of Cystic Lesions by Secondary Screening of Familial Pancreatic Cancer (FPC) Kindreds Is Not Associated with the Stratified Risk of CancerA R G Sheel, S Harrison, I Sarantitis, et al.
International Journal of Cancer|August 25, 2021
Early weight loss is an independent risk factor for shorter survival and increased side effects in patients with metastatic colorectal cancer undergoing first-line treatment within the randomized Phase III trial FIRE-3 (AIO KRK-0306)Lian Liu, Nicole Tonya Erickson, Ingrid Ricard, et al.
Pancreatology : Official Journal of the International Association of Pancreatology (IAP) ... [Et Al.]|May 8, 2020
International Consensus Guidelines for Risk Factors in Chronic Pancreatitis. Recommendations from the working group for the international consensus guidelines for chronic pancreatitis in collaboration with the International Association of Pancreatology, the American Pancreatic Association, the Japan Pancreas Society, and European Pancreatic ClubPéter Hegyi, Andrea Párniczky, Markus M Lerch, et al.
Gastroenterology|June 7, 2021
Tumor-Specific Delivery of 5-Fluorouracil-Incorporated Epidermal Growth Factor Receptor-Targeted Aptamers as an Efficient Treatment in Pancreatic Ductal Adenocarcinoma ModelsUjjwal M Mahajan, Qi Li, Ahmed Alnatsha, et al.
The Lancet. Oncology|August 31, 2016
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trialSebastian Stintzing, Dominik P Modest, Lisa Rossius, et al.
Pageof 64